APOA1 anticorps

N° du produit ABIN1724693

L’anticorps Souris Monoclonal anti-APOA1 a été validé pour WB et ELISA. Il convient pour détecter APOA1 dans des échantillons de Humain. Il y a 2+ publications disponibles.

Aperçu rapide pour APOA1 anticorps (ABIN1724693)

Antigène: APOA1 (Apolipoprotein A-I (APOA1))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp APOA1 est non-conjugé

Application: Western Blotting (WB), ELISA

Clone: 5F4F5

Détail du produit anti-APOA1 anticorps

Fonction: APOA1 Antibody

Purification: Ascitic fluid

Immunogène: Purified recombinant fragment of human APOA1 expressed in E. Coli.

Isotype: IgG1

Information d'application

Indications d'application: ELISA: 1/10000

Restrictions: For Research Use only

Stockage

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C,-20 °C

Stockage commentaire: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles.

Références pour anticorps anti-APOA1 (ABIN1724693)

Brown, Rea, Hamon, Hixson, Boerwinkle, Clark, Sing: "The contribution of individual and pairwise combinations of SNPs in the APOA1 and APOC3 genes to interindividual HDL-C variability." dans: Journal of molecular medicine (Berlin, Germany), Vol. 84, Issue 7, pp. 561-72, (2006) (PubMed).

Martina, Benso, Gigliardi, Masha, Origlia, Granata, Ghigo: "Short-term dehydroepiandrosterone treatment increases platelet cGMP production in elderly male subjects." dans: Clinical endocrinology, Vol. 64, Issue 3, pp. 260-4, (2006) (PubMed).

Détails sur APOA1

Antigène: APOA1 (Apolipoprotein A-I (APOA1))

Autre désignation: APOA1

Sujet: APOA1: apolipoprotein A-I, it is the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease. The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.

Poids moléculaire: 25 kDa

ID gène: 335

UniProt: P02647

Pathways: Regulation of Lipid Metabolism by PPARalpha, Production of Molecular Mediator of Immune Response, Lipid Metabolism